A Study of APX3330 in Patients With Advanced Solid Tumors

NCT03375086 | Completed Phase 1 FDA Drug

• 1 other identifier: APX_CLN_0011
• Study Type: interventional
• Target: 19
• Locations: 1 country
• Sites: 3

Brief Summary

This is a Phase 1, multi-center, open-label, dose-escalation oncology study of APX3330 in patients with advanced solid tumors.

Conditions

Cancer

Outcome Measures

Primary Outcomes (1)

• Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0

  Identification of the safety and tolerability of APX3330

  12 months

Secondary Outcomes (1)

• Any anti-tumor activity that may occur in patients receiving APX3330 using RECIST criteria

  18 months

Study Arms (1)

Single arm

EXPERIMENTAL

Patients will receive APX3330 orally, twice per day until disease progression

Drug: APX3330

Interventions

APX3330 DRUG

APX3330 will be supplied as 60 and 120 mg orally administered tablets. Patients will receive a fixed dose of APX3330 twice daily (i.e., bid) each day of a 21-day cycle. The starting dose of APX3330 will be a daily dose of 240 mg (i.e., 120 mg/dose bid). Doses will be increased until identification of a maximum tolerated dose or bio-effective dose, whichever is lower.

Also known as: E3330

Single arm

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Written informed consent must be obtained from the patient.
• Patient must be \> 18 years of age.
• Patient must have recurrent or advanced cancer (i.e., solid tumors) for whom standard therapy offers no curative potential.
• Evaluable disease by RECIST v1.1.
• Performance status (PS) of 0-2 on the Eastern Cooperative Oncology Group (ECOG) scale. Note: PS 2 patients can only participate if, in the assessment of the clinical investigator, and with the consent of the medical monitor, the patient has the ability to participate in the clinical study for a minimum of at least 2 cycles.
• \> 21 days from therapeutic radiation or chemotherapy (\>6 weeks from nitrosoureas and mitomycin C) and recovery to (NCI CTCAE v4.03) Grade ≤ 1 from all clinically significant toxicities related to prior therapies.
• Must have adequate organ function defined as:
• Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L.
• Platelet ≥ 100 x 10\^9/L.
• Hemoglobin ≥ 9 g/dL.
• Activated partial thromboplastin time/ partial thromboplastin time (aPTT/PTT) ≤ 1.5 x ULN
• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN). In the case of known (i.e., radiological or biopsy documented) liver metastasis, serum transaminase levels must be \< 5 x ULN.
• Total serum bilirubin ≤ 1.5 x ULN, (except for patients with known Gilbert's Syndrome ≤ 3 x ULN is permitted)
• Renal: Serum creatinine \< 2.0 x ULN or creatinine clearance ≥ 50 mL/min/1.73m\^2 for patients with serum creatinine levels above 2 x ULN.
• Agreement to use acceptable methods of contraception during the study and for at least 120 days after the last dose of APX3330 if sexually active and able to bear or beget children.

You may not qualify if:

• Diagnosed with another malignancy within the past 2 years (excluding a history of carcinoma in situ of the cervix, superficial non-melanoma skin cancer, superficial bladder cancer, or endometrial cancer that has been adequately treated, or stage 1 prostate cancer that does not require treatment).
• History of a major surgical procedure or a significant traumatic injury within 14 days prior to commencing treatment, or the anticipation of the need for a major surgical procedure during the course of the study.
• Patients who have been treated with an investigational agent within 21 days prior to the first dose of study drug.
• Concurrent serious (as determined by the Principal Investigator) medical conditions, including, but not limited to, New York Heart Association (NYHA) class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, active hepatitis B, C or HIV, or other significant co-morbid conditions that in the opinion of the investigator would impair study participation or cooperation.
• Impaired liver function Child-Pugh class B or C (score 7-15).
• Women who are pregnant or lactating.
• Patients with evidence of symptomatic brain metastases. Patients with treated (surgically excised or irradiated) and stable brain metastases are eligible assuming the patient has adequately recovered from treatment, the treatment was at least 28 days prior to initiation of study drug, and baseline brain computed tomography (CT) with contrast, or magnetic resonance imaging (MRI) within 14 days of initiation of study drug, is negative for new or worsening brain metastases
• Other concurrent chemotherapy, immunotherapy, radiotherapy or investigational therapy except for hormonal therapy (e.g., tamoxifen, etc.).
• Patients requiring palliative radiotherapy to lesions that are defined as target lesions by RECIST criteria at the time of study entry.

Sponsors & Collaborators

• Apexian Pharmaceuticals, Inc.: lead

Study Sites (3)

Indiana University Simon Cancer Center

Indianapolis, Indiana, 46202, United States

Location

START Midwest

Grand Rapids, Michigan, 49546, United States

Location

START San Antonio

San Antonio, Texas, 78229, United States

Location

Related Publications (5)

• Shah F, Logsdon D, Messmann RA, Fehrenbacher JC, Fishel ML, Kelley MR. Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic. NPJ Precis Oncol. 2017;1:19. doi: 10.1038/s41698-017-0023-0. Epub 2017 Jun 8.

  PMID: 28825044 BACKGROUND

• Jiang A, Gao H, Kelley MR, Qiao X. Inhibition of APE1/Ref-1 redox activity with APX3330 blocks retinal angiogenesis in vitro and in vivo. Vision Res. 2011 Jan;51(1):93-100. doi: 10.1016/j.visres.2010.10.008. Epub 2010 Oct 14.

  PMID: 20937296 BACKGROUND

• Safi Shahda, Nehal J. Lakhani, Bert O'Neil, Drew W. Rasco, Jun Wan, Amber L Mosley, Hao Liu, Mark R. Kelley, Richard Adam Messmann. A phase I study of the APE1 protein inhibitor APX3330 in patients with advanced solid tumors. Journal of Clinical Oncology. Volume 37: Issue 15_suppl.

  RESULT

• Kelley MR, Wan J, Liu S, Kpenu E, Wireman R, Mosley AL, Liu H, Lakhani NJ, Shahda S, O'Neil B, Opyrchal M, Messmann RA. A Phase I study targeting the APE1/ref-1 redox signaling protein with APX3330: First clinical agent targeting APE1/ref-1 in Cancer. Oncologist. 2025 Dec 19:oyaf423. doi: 10.1093/oncolo/oyaf423. Online ahead of print.

  PMID: 41423797 DERIVED

• Kelley MR, Wan J, Liu S, Kpenu E, Wireman R, Mosley AL, Liu H, Lakhani NJ, Shahda S, O'Neil B, Opyrchal M, Messmann RA. A Phase I study targeting the APE1/Ref-1 redox signaling protein with APX3330: First clinical agent targeting APE1/Ref-1 in Cancer. medRxiv [Preprint]. 2025 Apr 4:2025.04.03.25325173. doi: 10.1101/2025.04.03.25325173.

  PMID: 40236444 DERIVED

Related Links

• Company website

MeSH Terms

Conditions

Neoplasms

Interventions

E 3330

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Open-label, multi-center, dose escalation.

Study Record Dates

• First Submitted: November 21, 2017
• First Posted: December 15, 2017
• Study Start: January 30, 2018
• Primary Completion: August 18, 2018
• Study Completion: January 9, 2019
• Last Updated: September 7, 2020

Record last verified: 2020-09

Data Sharing

• IPD Sharing: Will not share

Locations

US (3)